More
More
Technology Platforms
With structure-based antigen design as the foundational technology.
More
Pipeline
Concentrated efforts towards the development of human papillomavirus (HPV) vaccines and multiple other innovative vaccines
and many other innovative vaccines
and many other innovative vaccines
More
Newsroom
-
BHGB Announces its In-house Developed Trivalent HPV Vaccine is Granted Priority Review by the CDE
2025-03-21
-
BHGB and Chengda Bio Announce the Start of a Phase Ⅱ Clinical Trial of the Recombinant 15-valent HPV Vaccine
2025-03-19
-
BHGB Announces Positive Data Readout from Interim Analysis of the Phase Ⅲ Trial of Nonavalent HPV Vaccine in Females
2025-02-28